Continued treatment with TG Therapeutics’ Briumvi (ublituximab) provides sustained clinical benefits for people with relapsing forms of multiple sclerosis (MS), particularly if started earlier. That’s according to data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials and their ongoing open-label…
Discussion
Several (OK, many) years ago, I was having lunch with a group of fellow Green Berets when a news story appeared on the TV. The report covered a recent tragedy, and during an interview with a survivor, it was mentioned that one of the victims had not survived because they…
The University of California San Francisco (UCSF) is teaming up with Nektar Therapeutics to study the potential of NKTR-0165, an experimental antibody that activates the tumor necrosis factor receptor type 2 (TNFR2), to treat multiple sclerosis (MS). UCSF neurologist Stephen L. Hauser,…
Breastfeeding for longer during infancy may delay the onset of multiple sclerosis (MS) and slow its progression for people who later develop the disease, according to a study from Turkey. Researchers found that adults with MS who had been breastfed for more than six months had less severe disease…
Canary Speech and Intermountain Ventures are collaborating to test whether subtle changes in a person’s voice can help identify multiple sclerosis (MS), potentially paving the way for noninvasive tools to diagnose the disease faster. The research will rely on Canary’s vocal biomarker technology and be led by Timothy…
Get regular updates to your inbox.
